Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds | Newswise Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cance...

Adding Immune Checkpoint Inhibitor to Standard Chemotherapy Regimen Improves Outcomes in Stage 3 Colon Cancer, Study Finds
www.newswise.com/articles/add...
#coloncancer #DanaFarberCancerInstitute #clinicaltrials #immunotherapycancertreatments

The Cancer AI Alliance #CAIA is a collaboration spearheaded by #FredHutch @fredhutch.bsky.social in collaboration with #DanaFarberCancerInstitute @danafarber.bsky.social, #MemorialSloanKettering @mskcancercenter.bsky.social, and Sidney Kimmel Comprehensive Cancer Center for AI in cancer research. 🧪

Geoffrey Shapiro Honored with MSCO Distinguished Researcher Award - OncoDaily Geoffrey Shapiro Honored with MSCO Distinguished Researcher Award / cancer, Dana-Farber Cancer Institute, Geoffrey Shapiro, Massachusetts Society of Clinical

Geoffrey Shapiro Honored with MSCO Distinguished Researcher Award

oncodaily.com/insight/msco...

#Cancer #DanaFarberCancerInstitute #MSCO #Medicine #Health #MSCODistinguishedResearcherAward #OncoDaily #Oncology

Sara Tolaney: HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy - OncoDaily Sara Tolaney: HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy / breast oncology, cancer, chemotherapy, Dana-Farber Cancer

HER3DXd showed pCR and ORR rates similar to standard multi-agent chemotherapy - Sara Tolaney

@danafarber.bsky.social
@stolaney1.bsky.social

oncodaily.com/blog/sara-to...

#BreastOncology #Cancer #Chemotherapy #Oncology #DanaFarberCancerInstitute #FightAgainstCancer #HER3DXd #OncoDaily

Dana-Farber Researchers to Present at the 2024 San Antonio Breast Cancer Symposium - OncoDaily Dana-Farber Researchers to Present at the 2024 San Antonio Breast Cancer Symposium / Adrienne G. Waks, Ann Partridge, Annual San Antonio Breast Cancer

Dana-Farber Researchers to Present at the 2024 San Antonio Breast Cancer Symposium

oncodaily.com/insight/201429

@sabcs.bsky.social
@danafarber.bsky.social

#BreastCancerSymposium #Cancer #COMETtrial #DanaFarberCancerInstitute #Olaparib #OlympiAtrial #OncoDaily #Oncology